Publication: The fuzzy world of precision medicine: deliberations of a precision medicine tumor board
Open/View Files
Date
2017
Published Version
Journal Title
Journal ISSN
Volume Title
Publisher
Future Medicine Ltd
The Harvard community has made this article openly available. Please share how this access benefits you.
Citation
McGraw, S. A., J. Garber, P. A. Jänne, N. Lindeman, N. Oliver, L. M. Sholl, E. M. Van Allen, et al. 2017. “The fuzzy world of precision medicine: deliberations of a precision medicine tumor board.” Personalized Medicine 14 (1): 37-50. doi:10.2217/pme-2016-0074. http://dx.doi.org/10.2217/pme-2016-0074.
Research Data
Abstract
Aim: To understand how a cancer precision medicine tumor board (CPM-TB) made choices about return of results. Materials & methods: Observed CPM-TB deliberations and completed in-depth interviews with committee members. Results: Responding to complex evidence of ambiguous significance, deliberations of the CPM-TB were predicated on analytic validity and clinical utility. Members had concerns both about potential harms due to returning results based on weak evidence and about withholding potentially meaningful results. Group dynamics and the clinical experiences of individual committee members shaped their work. Conclusion: Both scientific evidence and the social context surrounding deliberations of a CPM-TB influenced decisions about return of results. Subjective elements, while present in any scientific endeavor, may carry more weight in the face of ambiguous findings.
Description
Other Available Sources
Keywords
cancer, decision-making, genomics, precision medicine, sequencing, tumor board, US
Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material (LAA), as set forth at Terms of Service